Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-01-06

Clinical Trial Update: Safety and PK Study of BIBF 1120 in Japanese Patients With IPF [Phase 2]

View source ↗

Summary

A Phase 2 safety and pharmacokinetics study of Boehringer Ingelheim's BIBF 1120 (nintedanib) in Japanese patients with idiopathic pulmonary fibrosis has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BIBF 1120 (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2015-01-06